<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>General guidelines for monitoring and management of new airflow obstruction after hematopoietic stem cell transplantation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">General guidelines for monitoring and management of new airflow obstruction after hematopoietic stem cell transplantation</h1>
<div class="graphic"><div class="figure"><div class="ttl">General guidelines for monitoring and management of new airflow obstruction after hematopoietic stem cell transplantation</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Guidelines</td> </tr> <tr> <td class="indent1">A. Significant new airflow obstruction with a % predicted FEV<sub>1</sub> ≥70% <ol> <li>Initiate inhaled glucocorticoid therapy. Add inhaled long-acting beta agonist, if patient symptomatic. Treatment should continue until either FEV<sub>1</sub> becomes &lt;70% (see B below) or until GVHD resolves (ie, resolution of all reversible manifestations of GVHD without exacerbation for at least 6 months after discontinuation of all systemic immunosuppressive treatment) </li> <li>Other immunosuppressive treatment as indicated to control GVHD in other organs <ul> <li>Treatment should continue until either FEV<sub>1</sub> becomes &lt;70% (see B below), or until GVHD resolves (ie, resolution of all reversible manifestation of GVHD without exacerbation for at least 12 months after discontinuation of all systemic treatments) </li> </ul> </li> <li>Monitor PFTs or spirometry monthly for at least 3 months <ul> <li>If FEV<sub>1</sub> stabilizes, obtain PFTs or spirometry every 3 months for 1 year, then continue at 6 month intervals for 1 year and at 6 to 12 month intervals thereafter </li> <li>If FEV<sub>1</sub> continues to decrease, go to B below </li> </ul> </li> </ol> </td> </tr> <tr> <td class="indent1">B. Significant airflow obstruction with a FEV<sub>1</sub> &lt;70% with/without significant airtrapping by high resolution chest CT <ol> <li>Consider bronchoscopy to rule out an undetected infectious etiology for airflow obstruction, even if no radiographic opacity is apparent </li> <li>After infection has been ruled out, evaluate the patient's eligibility for clinical trial for treatment of BOS and initiate (or increase) prednisone dose to 1 mg/kg per day <ul> <li>Start standard chronic GVHD taper at 2 weeks </li> <li>Consider continuing inhaled glucocorticoids throughout prednisone therapy </li> </ul> </li> <li>If FEV<sub>1</sub> decreases further to &lt;70% during treatment, discuss changes of immunosuppressive treatment with transplant physician </li> <li>CMV monitoring in blood per standard practice </li> <li>Monitor PFTs or spirometry monthly for at least 3 months <ul> <li>If FEV<sub>1</sub> stabilizes, continue PFTs or spirometry every 3 months for 1 year </li> <li>If FEV<sub>1</sub> continues to decrease, go to C below </li> </ul> </li> </ol> </td> </tr> <tr> <td class="indent1">C. Glucocorticoid-resistant airflow obstruction defined as progressive decline of FEV<sub>1</sub> by ≥10% despite treatment with 1 mg/kg per day of prednisone (or similar glucocorticoids) <ol> <li>May consider increasing the dose of prednisone to 2 mg/kg per day for a maximum of 2 weeks, followed by a taper to reach a dose of 1 mg/kg per day by 2 to 4 weeks </li> <li>Another treatment must be considered and discussed with the transplant team </li> <li>Monitor CMV in blood per standard practice </li> <li>Monitor PFTs monthly for at least 3 months <ul> <li>If FEV<sub>1</sub> stabilizes, monitor PFTs every 3 months for 1 year </li> </ul> </li> </ol> </td> </tr> <tr> <td class="indent1">D. Additional considerations <ol> <li>Consider changing prophylaxis for encapsulated bacterial infection to azithromycin 250 mg on Mondays-Wednesdays-Fridays <ul> <li>Assure patient is receiving adequate prophylaxis for <em>Pneumocystis</em>, varicella virus, and herpes simplex virus infections </li> <li>Fungal prophylaxis per standard practice </li> </ul> </li> <li>Monitor CMV in blood per standard practice </li> <li>May continue inhaled glucocorticoids throughout prednisone therapy </li> <li>Discontinuation of inhaled glucocorticoid treatment can be considered 12 months after treatment with prednisone has been discontinued </li> </ol> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Before considering treatment, all potential infectious etiologies of airflow obstruction must be investigated and treated if present. Investigations that should be considered (directed by clinical symptoms), include sinus CT scan, nasal washes, sinus aspiration, high-resolution chest CT scan, sputum culture, bronchoalveolar lavage, and lung biopsy.</div><div class="graphic_footnotes">FEV<sub>1</sub>: forced expiratory volume in one second; GVHD: graft-versus-host disease; PFT: pulmonary function test; CT: computed tomography; CMV: cytomegalovirus.</div><div class="graphic_reference">Reproduced with permission of the American Society of Hematology, from Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood 2015; 125:606; permission conveyed through Copyright Clearance Center, Inc.</div><div id="graphicVersion">Graphic 105278 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
